Compare ADTN & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | PCRX |
|---|---|---|
| Founded | 1985 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 962.3M | 999.0M |
| IPO Year | 1996 | 2010 |
| Metric | ADTN | PCRX |
|---|---|---|
| Price | $8.92 | $26.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $15.50 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 2.1M | 506.2K |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 90.83 | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $1,083,807,000.00 | $541,533,000.00 |
| Revenue This Year | $11.09 | $6.78 |
| Revenue Next Year | $8.47 | $8.54 |
| P/E Ratio | ★ N/A | $384.57 |
| Revenue Growth | 17.46 | ★ 26.04 |
| 52 Week Low | $7.11 | $18.80 |
| 52 Week High | $19.98 | $27.64 |
| Indicator | ADTN | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.26 | N/A |
| Support Level | $8.36 | N/A |
| Resistance Level | $9.14 | N/A |
| Average True Range (ATR) | 0.59 | 0.00 |
| MACD | -0.12 | 0.00 |
| Stochastic Oscillator | 14.79 | 0.00 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.